Who Paid My Doc
Maranda Herner
Cardiovascular Disease Salt Lake City, UT Doctor of Osteopathy
NPI 1659741262 CMS profile 9500816
30 N 1900 E Rm 4A100, Ste B178, Salt Lake City, UT 84132
General payments
$719
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Maranda Herner of Salt Lake City, UT is reported in the CMS Open Payments database as having received $719 across 12 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 32nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $99 | 1 | |
| 2022 | General | $494 | 10 | |
| 2021 | General | $126 | 1 |
Beside peers
- Maranda Herner
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Maranda Herner were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Maranda Herner | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $450 | $127–$1,392 | $163 |
| 2020 | $0 | $242 | $77–$751 | $114 |
| 2021 | $126 | $335 | $101–$1,037 | $132 |
| 2022 | $494 | $395 | $121–$1,211 | $149 |
| 2023 | $0 | $443 | $136–$1,283 | $160 |
| 2024 | $99 | $450 | $136–$1,323 | $164 |
| 2025 | $0 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 25 billing codesPaid by Medicare
$6,136
Medicare patients
169
Services billed
250
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 69% | |
| Diabetes | 37% | |
| Heart failure | 37% | |
| Ischemic heart disease | 37% | |
| Arthritis | 34% | |
| Depression | 32% | |
| COPD | 30% | |
| Chronic kidney disease | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Utah
John Ryan
Cardiovascular Disease · Salt Lake City, UT
Robert Fowles
Cardiovascular Disease · Salt Lake City, UT
Brian Whisenant
Cardiovascular Disease · Murray, UT
Andrew Behunin
Cardiovascular Disease · Draper, UT
Jeffrey Osborn
Cardiovascular Disease · Salt Lake City, UT
James Fang
Cardiovascular Disease · Salt Lake City, UT
Related records
Cardiovascular Disease in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.